ABCB1 and cancer: Nilotinib, a second-generation of TKI, also inhibited the efflux function of ABCB1, ABCG2, and ABCC10 in cancer cells, thereby increasing the intracellular concentrations of the chemotherapeutic agents (e.g., PTX and doxorubicin) and potentiating their cytotoxic effects both in vitro and in vivo [28,68].